-
Something wrong with this record ?
A prospective study examining the incidence of asymptomatic and symptomatic lymphoceles following lymphadenectomy in patients with gynecological cancer
M. Zikan, D. Fischerova, I. Pinkavova, J. Slama, V. Weinberger, L. Dusek, D. Cibula,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NT13070
MZ0
CEP Register
- MeSH
- Adult MeSH
- Incidence MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Recurrence, Local surgery MeSH
- Lymph Node Excision adverse effects statistics & numerical data MeSH
- Lymphocele epidemiology MeSH
- Young Adult MeSH
- Genital Neoplasms, Female surgery MeSH
- Prospective Studies MeSH
- Risk Factors MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Czech Republic MeSH
OBJECTIVE: To identify the incidence of asymptomatic and symptomatic (i.e., causing pain, hydronephrosis, venous thrombosis, acute lymphedema of the lower or urinary urgency) lymphoceles, as well as risk factors for their development, through a prospective study of patients undergoing sole pelvic or combined pelvic and paraaortic lymphadenectomy for gynecological cancer. METHODS: Patients with endometrial, ovarian or cervical cancer scheduled for sole pelvic or combined pelvic and paraaortic lymphadenectomy as a primary surgical treatment or salvage surgery for recurrence were enrolled at single institution from February 2006 to November 2010 and prospectively followed up with ultrasound. RESULTS: Of 800 patients who underwent sole pelvic or combined pelvic and paraaortic lymphadenectomy for gynecological cancer, the overall incidence of lymphoceles was 20.2%, with symptomatic lymphoceles occurring in 5.8% of all patients. Lymphoceles are predominantly located on the left pelvic side wall. Lymphadenectomy in ovarian cancer, a higher number of lymph nodes obtained (>27), and radical hysterectomy in cervical cancer were found to be independent risk factors for the development of symptomatic lymphoceles. CONCLUSIONS: The overall incidence of lymphocele development after lymphadenectomy for gynecological cancer remains high. However, the majority of lymphoceles are only incidental finding without clinical impact. A symptomatic lymphocele is an uncommon event, occurring in only 5.8% of patients. Symptomatic lymphoceles tend to develop earlier than asymptomatic. Although such risk factors are hard to avoid, patients known to be at an increased risk of developing symptomatic lymphoceles can be counseled appropriately and followed up for specific symptoms relating to lymphocele development.
Institute of Biostatistics and Analyses Masaryk University Kamenice 126 3 Brno 625 00 Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15031450
- 003
- CZ-PrNML
- 005
- 20181109142818.0
- 007
- ta
- 008
- 151005s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ygyno.2015.02.016 $2 doi
- 035 __
- $a (PubMed)25720294
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Zikán, Michal, $u Gynecological Oncology Center, Department of Obstetrics and Gynecology, Charles University in Prague, First Faculty of Medicine and General University Hospital, Apolinarska 18, Prague 128 00, Czech Republic. Electronic address: michal.zikan@lf1.cuni.cz. $d 1976- $7 xx0096708
- 245 12
- $a A prospective study examining the incidence of asymptomatic and symptomatic lymphoceles following lymphadenectomy in patients with gynecological cancer / $c M. Zikan, D. Fischerova, I. Pinkavova, J. Slama, V. Weinberger, L. Dusek, D. Cibula,
- 520 9_
- $a OBJECTIVE: To identify the incidence of asymptomatic and symptomatic (i.e., causing pain, hydronephrosis, venous thrombosis, acute lymphedema of the lower or urinary urgency) lymphoceles, as well as risk factors for their development, through a prospective study of patients undergoing sole pelvic or combined pelvic and paraaortic lymphadenectomy for gynecological cancer. METHODS: Patients with endometrial, ovarian or cervical cancer scheduled for sole pelvic or combined pelvic and paraaortic lymphadenectomy as a primary surgical treatment or salvage surgery for recurrence were enrolled at single institution from February 2006 to November 2010 and prospectively followed up with ultrasound. RESULTS: Of 800 patients who underwent sole pelvic or combined pelvic and paraaortic lymphadenectomy for gynecological cancer, the overall incidence of lymphoceles was 20.2%, with symptomatic lymphoceles occurring in 5.8% of all patients. Lymphoceles are predominantly located on the left pelvic side wall. Lymphadenectomy in ovarian cancer, a higher number of lymph nodes obtained (>27), and radical hysterectomy in cervical cancer were found to be independent risk factors for the development of symptomatic lymphoceles. CONCLUSIONS: The overall incidence of lymphocele development after lymphadenectomy for gynecological cancer remains high. However, the majority of lymphoceles are only incidental finding without clinical impact. A symptomatic lymphocele is an uncommon event, occurring in only 5.8% of patients. Symptomatic lymphoceles tend to develop earlier than asymptomatic. Although such risk factors are hard to avoid, patients known to be at an increased risk of developing symptomatic lymphoceles can be counseled appropriately and followed up for specific symptoms relating to lymphocele development.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a nádory ženských pohlavních orgánů $x chirurgie $7 D005833
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a lymfadenektomie $x škodlivé účinky $x statistika a číselné údaje $7 D008197
- 650 _2
- $a lymfokela $x epidemiologie $7 D008210
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a lokální recidiva nádoru $x chirurgie $7 D009364
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a mladý dospělý $7 D055815
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Fischerová, Daniela $u Gynecological Oncology Center, Department of Obstetrics and Gynecology, Charles University in Prague, First Faculty of Medicine and General University Hospital, Apolinarska 18, Prague 128 00, Czech Republic. $7 xx0074804
- 700 1_
- $a Pinkavová, Ivana, $u Gynecological Oncology Center, Department of Obstetrics and Gynecology, Charles University in Prague, First Faculty of Medicine and General University Hospital, Apolinarska 18, Prague 128 00, Czech Republic. $d 1976- $7 xx0103207
- 700 1_
- $a Sláma, Jiří $u Gynecological Oncology Center, Department of Obstetrics and Gynecology, Charles University in Prague, First Faculty of Medicine and General University Hospital, Apolinarska 18, Prague 128 00, Czech Republic. $7 xx0105772
- 700 1_
- $a Weinberger, Vít, $u Faculty of Medicine, Department of Obstetrics and Gynecology, Masaryk University, Obilni trh 526/11, Brno 602 00, Czech Republic. $d 1978- $7 mub2014810789
- 700 1_
- $a Dušek, Ladislav, $u Institute of Biostatistics and Analyses, Masaryk University, Kamenice 126/3, Brno 625 00, Czech Republic. $d 1967- $7 mzk2003181727
- 700 1_
- $a Cibula, David, $u Gynecological Oncology Center, Department of Obstetrics and Gynecology, Charles University in Prague, First Faculty of Medicine and General University Hospital, Apolinarska 18, Prague 128 00, Czech Republic. $d 1968- $7 jo20000074072
- 773 0_
- $w MED00001958 $t Gynecologic oncology $x 1095-6859 $g Roč. 137, č. 2 (2015), s. 291-298
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25720294 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20151005 $b ABA008
- 991 __
- $a 20181109142858 $b ABA008
- 999 __
- $a ok $b bmc $g 1092326 $s 914576
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 137 $c 2 $d 291-298 $e 20150224 $i 1095-6859 $m Gynecologic oncology $n Gynecol Oncol $x MED00001958
- GRA __
- $a NT13070 $p MZ0
- LZP __
- $a Pubmed-20151005